ARCHIVES

Defying critics, von Eschenbach describes hands-on role at NCI while running FDA. NCI is unified behind 2015 goal, he says.

This article is from The Cancer Letter archive.

Vol. 31 No. 45 | December 9, 2005

Download PDF Visit The Full Archive

Related Articles

Petition Filed To Revoke NlH License To Use Radioactive Materials

October 20, 1995

Guidelines Adopted For Pathology Review

February 22, 1980

FDA Vs. NCI: Nothing Has Changed; Chabner “Frustrated” By Flutamide Delay

October 21, 1988

In Brief: NCI To Supply Maytansine For Several Phase I Studies; Holleb Urges Referrals To “Experts”

March 26, 1976

Phase II Study Cohort Fails To Overcome Erlotinib Resistance

April 26, 2013

NCI To Fund 840 Competing Grants In FY 1991; No Downward Negotiations, But Careful Review

December 7, 1990